Otitis Media News and Research

RSS

Acute otitis media (AOM) is a common childhood disease with important ramifications to the overall health of infants and young children. The peak incidence of AOM occurs at 6 to 18 months of age, but it can also occur in older children. Complications of AOM include persistent middle ear effusion, chronic otitis media, transient hearing loss, or speech delays.

Immunoregulatory genes modulate otitis media risk

Variation in genes involved in immunity influences children’s susceptibility to developing otitis media, according to research by a US team.

28 Apr 2014

Pediatric viral respiratory tract infection often complicated by bacterial sinusitis

Nearly 1 in 10 cases of viral upper respiratory tract infections in infants and young children is complicated by acute bacterial sinusitis, often in conjunction with acute otitis media, a longitudinal cohort study has found.

22 Apr 2014

Rare case of tuberculous otitis media described

South Korean researchers have reported a rare case of tuberculous otitis media and say that ear tuberculosis should be considered in patients presenting with otitis media complicated by facial paralysis.

7 Apr 2014

Aston University tackles 'glue ear' problem with hearing test app

Aston University is tackling the problem of 'glue ear' in children with a hearing test app for any concerned families.

4 Apr 2014

URTI risk factor for chronic, recurrent otitis media

Results from a meta-analysis indicate that upper respiratory tract infection increases the odds of chronic or recurrent otitis media over sixfold.

3 Feb 2014

Cord blood vitamin D linked to pediatric RTI risk

South Korean researchers say that encouraging pregnant women to spend more time outdoors or to increase their vitamin D supplementation may reduce the number of respiratory tract infections in their infants.

13 Jan 2014

AOM associated with significant increases in direct costs incurred by consumers, health care system

Acute otitis media, or ear infection, is the most common ailment among kids of preschool age and younger in the U.S., primarily because these children have immature middle-ear drainage systems, higher exposure to respiratory illnesses and undeveloped immune systems.

10 Jan 2014

Implanting tubes in ears is less likely to improve long-term cognitive and functional development

Watchful waiting or ear tube surgery? It is a decision faced by millions of families of children with recurrent or chronic otitis media with effusion (non-infected fluid in the middle ear) each year.

6 Jan 2014

Duration of common pediatric respiratory infections estimated

An international research team has systematically reviewed the literature to formulate up-to-date estimates of the duration of common childhood respiratory tract infections.

24 Dec 2013

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

GlaxoSmithKline plc announced today that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK's FluLaval® Quadrivalent reduced flu cases among children ages 3-8 by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%.

12 Dec 2013

Air pollution link to early childhood pneumonia

European research shows that exposure to elevated levels of air pollutants is associated with an increased risk for pneumonia before the age of 3 years, and particularly in the first year of life.

18 Nov 2013

Smartphone-enabled otoscope provides clear images of ear tympanic membrane

A new, smartphone-enabled otoscope provides clear, transmittable images of the ear drum, or tympanic membrane, which someday may allow for ear infection diagnosis without a visit to the doctor's office, according to an abstract presented Monday, Oct. 28, at the American Academy of Pediatrics National Conference and Exhibition in Orlando.

28 Oct 2013

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.

18 Oct 2013

Short-term hearing loss during childhood may lead to persistent hearing deficits

Short-term hearing loss during childhood may lead to persistent hearing deficits, long after basic auditory sensitivity has returned to normal. The processing of sound in the brain is shaped by early experience.

1 Oct 2013

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer Inc. announced today the company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), received European approval for an expanded indication to include adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae (S. pneumoniae).

10 Jul 2013

Wellcome Trust-funded study could point to new therapies for glue ear

Important new insights into how the brain compensates for temporary hearing loss during infancy, such as that commonly experienced by children with glue ear, are revealed in a research study in ferrets.

28 Jun 2013

Common sugar molecule promising target for development of broad-spectrum vaccine

Developing new vaccines to protect against diseases that plague humans is fraught with numerous challenges-one being that microbes tend to vary how they look on the surface to avoid being identified and destroyed by the immune system. However, researchers from Brigham and Women's Hospital (BWH) have discovered a sugar polymer that is common on the cell surface of several pathogens.

28 May 2013

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age.

From Pfizer, Inc. 29 Apr 2013

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Pfizer Inc. presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine Diphtheria CRM197 Protein)in adults infected with human immunodeficiency virus (HIV).

5 Mar 2013

Amoxicillin effectiveness: an interview with Prof Paul Little, University of Southampton

Amoxicillin is a broad spectrum penicillin, and in the UK is one of the most frequently used antibiotics. It is commonly used either on its own or, where there are particular concerns about resistance, in combination as Co-amoxiclav (as Amoxicillin-clavulanic acid) which extends its anti-bacterial spectrum.

1 Mar 2013